Prostate Cancer - Results from #2360

Association between hospital competition and quality of prostate cancer care. August 9, 2023

Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer. August 9, 2023

Novel non-MRI imaging techniques for primary diagnosis of prostate cancer: micro-ultrasound, contrast-enhanced ultrasound, elastography, multiparametric ultrasound, and PSMA PET/CT. August 8, 2023

Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate-specific antigen concentrations. August 8, 2023

A Systematic Review of Patient Race, Ethnicity, Socioeconomic Status, and Educational Attainment in Prostate Cancer Treatment Randomised Trials-Is the Evidence Base Applicable to the General Patient Population? August 8, 2023

A multi-institutional study of 1,111 men with 4K score, multiparametric magnetic resonance imaging, and prostate biopsy. August 8, 2023

The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer. August 8, 2023

A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer. August 7, 2023

Results from the PRIMA Trial: Comparison of the STHLM3 Test and Prostate-specific Antigen in General Practice for Detection of Prostate Cancer in a Biopsy-naïve Population. August 7, 2023

68Ga-PSMA PET/CT for Response Evaluation of 223Ra Treatment in Metastatic Prostate Cancer. August 7, 2023

Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) MRI Scoring to Predict Clinical Outcomes in Active Surveillance for Grade Group 1 Prostate Cancer. August 7, 2023

Clinicopathological and oncological significance of persistent prostate-specific antigen after radical prostatectomy: A systematic review and meta-analysis. August 7, 2023

Androgen-regulated stromal complement component 7 (C7) suppresses prostate cancer growth. August 7, 2023

A multivalent peptoid conjugate modulates androgen receptor transcriptional activity to inhibit therapy-resistant prostate cancer. August 7, 2023

NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer. August 7, 2023

The role of nuclear medicine tracers for prostate cancer surgery: from preoperative to intraoperative setting. August 4, 2023

Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression. August 4, 2023

Regional differences in stage distribution and rates of treatment for adrenocortical carcinoma across United States SEER registries. August 4, 2023

Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims. August 4, 2023

New drug approvals in prostate cancer and their effect on the treatment landscape. August 4, 2023

Page 119 of 1439